By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Stockholders of Clarient have tendered around 80 percent of their shares to GE Healthcare as the initial offering period for the acquisition closed last night.

GE Healthcare launched the $580 million acquisition offer for the molecular diagnostics and imaging firm in early November.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.